简 EN 繁
简 EN 繁

Please enter the information you want to find

Hot key words：
Hyaluronidase xxx
News Center News Center

News Center

2025.12.10

​Shanghai Bao Pharma Successfully Listed on the Hong Kong Stock Exchange, Ushering in a New Era of Recombinant Biologics

View details
​Shanghai Bao Pharma Successfully Listed on the Hong Kong Stock Exchange, Ushering in a New Era of Recombinant Biologics
Exploring the Frontiers of Clinical Innovation: Bao Pharma Participating in the National Xenotransplantation Mega-Project
2025.12.12

Exploring the Frontiers of Clinical Innovation: Bao Pharma Participating in the National Xenotransplantation Mega-Project

View details
【News】Bao Pharma's Recombinant Human Hyaluronidase Successfully Registered in the U.S. FDA DMF
2025.05.16

【News】Bao Pharma's Recombinant Human Hyaluronidase Successfully Registered in the U.S. FDA DMF

View details
【News】 Bao Pharma's "KJ103 for Injection" (Recombinant Immunoglobulin G-degrading Enzyme Ricefidase) Receives NMPA Approval for New Indication Clinical Trial
2025.04.29

【News】 Bao Pharma's "KJ103 for Injection" (Recombinant Immunoglobulin G-degrading Enzyme Ricefidase) Receives NMPA Approval for New Indication Clinical Trial

View details
World's First Low-Immunogenic IgG-Degrading Enzyme — Ricefidase Phase III Clinical Trial Officially Launched
2025.04.21

World's First Low-Immunogenic IgG-Degrading Enzyme — Ricefidase Phase III Clinical Trial Officially Launched

View details
123